Literature DB >> 14711532

Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome.

Shahar Kol1.   

Abstract

OBJECTIVE: To review the available knowledge on the use of GnRH agonist for ovulation triggering as a means to prevent ovarian hyperstimulation syndrome (OHSS). DESIGN(S): Review of pertinent English language studies published over the past 15 years. RESULT(S): The available literature suggests that while GnRH agonist effectively induces final oocyte maturation and ovulation, it also completely and reliably prevents clinically significant OHSS. The mechanism of action in the context of OHSS prevention involves complete, quick, and irreversible luteolysis CONCLUSION(S): Controlled ovarian stimulation protocols based on GnRH antagonist to prevent premature LH rise and GnRH agonist for ovulation triggering provide a safe and OHSS-free clinical environment. Adequate luteal support compensates for luteolysis and assures good clinical outcome. The fertility community is urged to adopt these protocols. This will make OHSS a disease of the past.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14711532     DOI: 10.1016/j.fertnstert.2003.05.032

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  27 in total

Review 1.  GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?

Authors:  S Kol; I Solt
Journal:  J Assist Reprod Genet       Date:  2008-02-07       Impact factor: 3.412

Review 2.  Ovarian manipulation in ART: going beyond physiological standards to provide best clinical outcomes.

Authors:  Israel Ortega; Juan A García-Velasco; Antonio Pellicer
Journal:  J Assist Reprod Genet       Date:  2018-07-28       Impact factor: 3.412

3.  GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation.

Authors:  Kutluk Oktay; Ilgın Türkçüoğlu; Kenny A Rodriguez-Wallberg
Journal:  Reprod Biomed Online       Date:  2010-03-06       Impact factor: 3.828

4.  Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome.

Authors:  Kathleen E O'Neill; Suneeta Senapati; Anuja Dokras
Journal:  Fertil Steril       Date:  2014-11-06       Impact factor: 7.329

Review 5.  Pharmaceutical options for triggering of final oocyte maturation in ART.

Authors:  Juan Carlos Castillo; Peter Humaidan; Rafael Bernabéu
Journal:  Biomed Res Int       Date:  2014-07-15       Impact factor: 3.411

6.  Severe ovarian hyperstimulation syndrome: Can we eliminate it through a multipronged approach?

Authors:  Nikita Naredi; S K Singh; Prasad Lele; N Nagraj
Journal:  Med J Armed Forces India       Date:  2017-06-19

Review 7.  Overriding follicle selection in controlled ovarian stimulation protocols: quality vs quantity.

Authors:  Richard L Stouffer; Mary B Zelinski-Wooten
Journal:  Reprod Biol Endocrinol       Date:  2004-06-16       Impact factor: 5.211

8.  HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.

Authors:  Jigal Haas; Alon Kedem; Ronit Machtinger; Shir Dar; Ariel Hourvitz; Gil Yerushalmi; Raoul Orvieto
Journal:  J Ovarian Res       Date:  2014-04-03       Impact factor: 4.234

9.  Persistent ascites resolving with gonadotropin-releasing-hormone-agonist 18 months after hospitalization for severe ovarian hyperstimulation syndrome.

Authors:  Cihan Comba; Funda Gungor Ugurlucan; Ercan Bastu; Ahmet Cem Iyibozkurt; Samet Topuz
Journal:  Arch Gynecol Obstet       Date:  2013-07-12       Impact factor: 2.344

10.  Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.

Authors:  Raoul Orvieto; Christos A Venetis; Human M Fatemi; Thomas D'Hooghe; Robert Fischer; Yulia Koloda; Marcos Horton; Michael Grynberg; Salvatore Longobardi; Sandro C Esteves; Sesh K Sunkara; Yuan Li; Carlo Alviggi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-10       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.